



19th November 2025 | India Habitat Centre, New Delhi

0900 – 1000 Hrs.	Registration		
1000 – 1045 Hrs.	INAUGURAL SESSION		
1000 – 1010 Hrs.	Opening Remarks	Ms. Amita Sarkar Deputy Director General Confederation of Indian Industry (CII)	
1010 – 1025Hrs.	Welcome Address	Dr. Arun Atrey Chairman, National Task Force on Wellbeing, CII & Managing Director & CEO, Zenex Animal Health	
1025 – 1045 Hrs.	Theme Address	Dr. Praveen Malik Chief Executive Officer Agrinnovate India Ltd	
1045 – 1100 Hrs. Tea Break			
1040 1100 1110. Tota Broak			
1100– 1200 Hrs. SESSION I: Animal Health Industry and Its Role in National Economics and Atmanirbhar Bharat			

1100- 1200 Hrs.	SESSION I: Animal Health Industry and Its Role in National Economics and Atmanirbhar Bharat			
	The Animal Health Industry is a critical driver of India's rural prosperity and economic growth. By enabling disease prevention and fostering self-reliance through indigenous R&D and reduced import dependency, the sector is shaping India's journey towards <i>Atmanirbhar Bharat</i> . This session will highlight its economic significance and future potential.			
Moderator				
	Dr. Arun Atrey Chairman, National Task Force on Animal Wellbeing, CII & Managing Director & CEO, Zenex Animal Health			
	Speakers			
	Dr. A. Visala Joint Drugs Controller (India) Central Drugs Standard Control Organization Dr. Praveen Malik Chief Executive Officer Agrinnovate India Ltd			
	Dr. K Anand Kumar Managing Director Indian Immunological Ltd			

1200 – 1300 Hrs.	SESSION II: Faster Access, Smarter Care: Reforms and Digital Solutions for Animal Health		
	The future of animal healthcare in India depends on a strong regulatory framework and the adoption of innovative technologies. This session will delve into the key regulatory reforms required to enable faster approvals and wider access to therapeutics, biologicals, and diagnostics—ensuring timely disease prevention and control. It will also highlight how digital platforms, smart diagnostics, and data-driven tools can transform animal health management, improve surveillance and strengthen India's animal health economy. Together, these approaches are pivotal to building a resilient, self-reliant and globally competitive animal health ecosystem.		
Moderator & Presenter			
	Dr. Yash Goyal Co-Chairman, National Task Force on Animal Wellbeing, CII & Managing Director MSD Animal Health		
	Speakers		
	Dr. Pronab Dhar Principal Scientist & Head Standardization Division ICAR-Indian Veterinary Research Institute Dr. R P Singh Director ICAR – National Institute on Foot and Mouth Disease Dr. Santosh Wakchaure Veterinary Techno-commercial Lead - Jio Cattle Monitoring System Jio Platforms Limited (JPL)		

1300 – 1400 Hrs.	Networking Lunch		
1400 – 1500 Hrs.	SESSION III: From Awareness to Innovation: Driving Companion Animal Health		
	India's companion animal sector is expanding rapidly, driven by rising pet ownership and changing consumer lifestyles. Yet, the industry faces key challenges, low awareness on balanced pet nutrition, limited access to specialized veterinary care, fragmented supply chains, and high reliance on imports for quality pet food and supplements. This session will delve into the thrust areas needed to unlock growth for indigenous nutrition solutions, developing regulatory clarity, fostering innovation in functional and preventive nutrition, expanding digital distribution channels, and enhancing veterinary—pet parent engagement.		
Moderator			
	Mr. Salil Murthy Managing Director Mars Petcare India		
	Speakers		
	Ms. Priyanka Mehra Scientist E/ Director Food & Agricultural Department Bureau of Indian Standards		
	Ms. Pallavi Anand Business Head, South Asia Region Nestlé Purina Petcare		
	Mr. Dhanu Roy Founder, Director Right4Paws		

Mr. Aniruddha Rajurkar Chief Executive Officer SAVA Healthcare

1500 – 1600 Hrs.	SESSION IV: India's Rise as a Global Hub for Animal Health Excellence		
	India's animal health industry holds immense potential to emerge as a global hub for innovation, manufacturing, and exports. With its skilled talent pool and expanding domestic market, India is well-positioned to drive indigenous R&D, scale world-class manufacturing, and supply affordable, high-quality therapeutics, vaccines, and diagnostics to global markets. However, realizing this potential requires addressing key challenges such as regulatory harmonization, quality standards, investment in innovation, and building robust global partnerships. This session will explore strategies to strengthen India's export ecosystem, foster innovation-led growth, and position the country as a trusted leader in the global animal health value chain.		
Moderator			
	Mr. Vijay Teng Co-Chairman, National Task Force on Animal Wellbeing, CII & President, Global Animal Health, Intas Pharmaceuticals		
	Speakers		
	Dr. Yash Goyal Managing Director MSD Animal Health		
	Ms. Ashwini Deshpande Managing Director India & Regional Director India, Indonesia and South Asia Zoetis		
	Dr. Sindura Ganapathi PSA Fellow Office of the Principal Scientific Adviser to the Government of India		
	Mr. Gaurav Marathe Managing Director & Head of India Lincoln International Advisors Private Limited		

4000 4045 11	Naturalia a Tan Durali
1600 – 1615 Hrs.	Networking Tea Break

1615 – 1715 Hrs.	SESSION V: Evidence and Integration: The Role of Alternate Medicine in Veterinary Science		
	With rising concerns around antibiotic resistance, drug residues, and long-term animal health, there is a growing interest in integrating alternate medicine systems like Ayurveda into veterinary care. Yet, challenges remain—lack of standardized formulations, limited scientific validation, regulatory ambiguity, and practical integration into modern veterinary practice continue to pose barriers. In this session, experts will present case studies, emerging research, and practical strategies to evaluate efficacy, ensure safety, and align traditional knowledge with scientific rigor.		

Moderator Moderator			
	Dr. Sandip Joshi Head of AHD Himalaya Wellness Company		
	Speakers		
	Dr. Shivi Maini General Manager - Technical Indian Herbs Dr. Sumit Joshi Head – Clinical Research Zenex Animal Health Ms. Shreya Agarwal Managing Director Satya Pharmaceuticals Ayurveda		

1715 – 1725 Hrs.	Vote of Thanks
	Dr. Shirish Nigam Managing Director EW Nutrition South Asia Ltd.







19 November 2025 India Habitat Centre, New Delhi

CORPORATE PROFILES







With a rich legacy of nearly seven decades in serving Animal Health in India, Zenex Animal Health is the leading Indian animal health Company in Animal Healthcare industry in India. The company offers products for Large & Small Ruminants, Poultry and Companion Animals and is uniquely positioned as an organization which offers extensive range of products including herbal products. Zenex Animal Health enjoys a leadership position in many product segments in livestock and poultry healthcare.

The company keeps on exploring newer opportunities to serve the unmet needs of animal healthcare fraternity in India and has the credit of introducing one of the highest numbers of innovative & first to the market products. Recently, Zenex Animal Health has developed a first ever novel strain, Bacillus Siamensis ZMT02, for probiotic use in poultry and NBIOTIC, an innovative Phytobiotic, which boosts gut health, enhances immunity and thus drives sustainable animal performance.

The Company's scientific database complements over 810 research trials conducted by the herbal division. Over the years, its products have also been the subject of 120+ notable research works of MVSc and PhD scholars from different parts of the world.

Zenex Animal Health has two state-of-the-art manufacturing facilities at Haridwar (Uttarkhand) and Baddi (Himachal Pradesh), dedicated to manufacture veterinary products for domestic and international markets.

With the help of its highly trained field force and wide distribution network, Zenex Animal Health provides solution based technical services to the dairy and poultry farming communities on various health issues and also to improve productivity.

Besides domestic prominence, the company has made significant strides in international business and with a focused approach exports to across Asia, Africa, CIS, EU, LATAM, MENA regions.

For its decades of excellence and innovation in animal health care industry, the Company has been recognized with internationally acclaimed awards like S&P Global Animal Health Awards selected as "Best Company in the Rest of the World" in 2023 and 'The Best Animal Health Company in India, Middle East & Africa by Animal Pharm (UK) in 2018, 2016 and 2015 and several national awards.

Zenex is backed by a blue-chip set of investors – Multiples Private Equity, RARE Enterprises, CPP Investments, IFC Washington, Asian Development Bank, State Bank of India and some of India's most illustrious HNIs.







INTAS ANIMAL HEALTH

Passion for Quality. Compassion for Life.

Who We Are

Intas Animal Health is one of India's leading Animal Health companies, consistently ranked among the top three in the industry. For over two decades, we have been committed to redefining Animal Health Care through high-quality, science-driven, and customer-centric solutions for both Production and Companion Animals.

Our Legacy: Strength Backed by Intas

As part of Intas Pharmaceuticals, a global healthcare organization with FY25 revenues of USD 2.5 billion, Intas Animal Health benefits from world-class capabilities in manufacturing, R&D, biologics, and compliance. This foundation enables us to deliver Animal Health solutions that meet global benchmarks of quality and reliability.

Comprehensive Portfolio

We offer a complete range of veterinary products, including:

- Pharmaceuticals
- Biologicals
- Nutraceuticals
- Feed Additives

Our solutions support veterinarians, farmers, and pet families with trusted, effective, and accessible care.

Built on Innovation and Quality

- Strong in-house R&D backed by scientific expertise
- Dedicated and advanced manufacturing infrastructure with stringent quality systems
- Reliable supply supported by global capabilities
- Proven performance across diverse therapeutic and nutritional categories



Intas Animal Health operates in **35+ countries**, delivering products that meet international standards of excellence.

Our Strategic Vision

Our five-year strategic growth roadmap, Intas Animal Health is focused on:

- Strengthening leadership in India across Production and Companion Animal segments
- Expanding our footprint in emerging markets
- Accelerating Companion Animal growth in EMENA, North America and Latin America
- Building a future-ready, innovation-led portfolio

Our goal is clear: to be India's leading Animal Health organization with a strong global presence.

Accord Animal Health: Our Global Markets Arm

Through Accord Animal Health, we bring effective, convenient, and affordable Companion Animal medicines to global markets. Supported by Accord Healthcare's global expertise, we empower veterinarians in these markets with high-quality therapeutic solutions.

Our Commitment

At Intas Animal Health, we stand for:

- Scientific Excellence
- Ethical Practices
- Customer Focus
- Quality Without Compromise

Driven by compassion and innovation, we remain committed to uplifting the veterinary profession and advancing the future of animal health.







Himalaya Wellness Company

The Himalaya Drug Company was founded in 1930 by Mr. M Manal. His vision was to bring the traditional Indian science of Ayurveda to society in a contemporary form. He wanted to rekindle the 5000-year-old Ayurvedic principles and extract their benefits to cater to the healthcare needs of modern society. Himalaya strives to integrate principles of traditional medicine with modern science and is a pioneer in the field of scientifically validated herbal healthcare.

Having developed a few pet healthcare products for the Cayman market, in 1998, Himalaya formally launched a range of herbal formulations for commercial livestock. Encouraged by feedback from cattle and poultry owners that they refer herbal feed supplements for their animals, Himalaya stepped into the animal healthcare segment, researching and formulating a range of herbal products to improve the health of farm animals. In the year 2000, Himalaya extended the animal health range and launched a special, herbal Companion Care range for pets. Veterinarians, dairy farmers, and animal lovers increasingly opted for Himalaya's animal health products because of our herbal ingredients, safety, and efficacy.

Right from Liv.52, one of India's top-selling hepatoprotectives, to trusted brands such as HimTOX, PhytoGrow, PulmoBoost, Geriforte VET, HimCal, Anxocare, the Erina range, and the newly launched HimChelate, HimTRACE, HimLay, PondSHIELD, HimROP Plus, Healthy Treats, and Healthy PET food we continue to develop safe and efficacious herbal products. Our products go through a similar cycle of drug development as in allopathic drugs, from toxicity and stability studies to phase I-IV clinical trials. Each product undergoes an average of six to eight years of research, which includes several clinical studies. Results of these studies are published in Indian and international journals.

We follow international guidelines for Good Agricultural Practices (GAP) and Good Harvesting Practices (GHP). We are an ISO 9001:2000 certified company and follow Good Clinical Practices (GCP), Good Laboratory Practices (GLP), and Good Manufacturing Practices (GMP). As we work closely with nature, we are deeply committed to caring for the environment. Himalaya has been awarded the ISO 14001:2004 certificate, a globally recognized standard for environment management.

Today, Himalaya's products have been endorsed by more than 45,000 veterinarians and around 8,000 farmers to become a globally renowned brand. This Therapeutic Index introduces you to the world of our products and research. It provides information on our entire Animal Health range.

We hope it serves its purpose of being a handy digest of scientific information about our products.

Thank you

Himalaya wellness.







About MSD Animal Health

At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. The company is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. The company's innovative portfolio includes technology, products and solutions to help, improve or enhance animal management and health outcomes across Livestock and Companion Animal species. Healthier animals mean a sustainable food supply, protection for humans against diseases passed from animals, and longer, healthier lives for pets.

Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. We are committed to our company's core values of innovation and scientific excellence, ethics and integrity, placing customers first and respect for people.

MSD Animal Health has a rich history of innovation, commitment to research and entrepreneurship in animal health dating back over 70 years. It invests extensively in dynamic and comprehensive R&D and technological resources and a modern, global supply chain. The company is present in more than 50 countries, while its products are available in some 150 markets.

Updated: June 2024









SAVA HEALTHCARE LIMITED

Corporate Brief

SAVA Healthcare Limited, headquartered in India, operates a Health Canada and PIC/s certified manufacturing facility in Gujarat, alongside an advanced R&D centre in Pune. The company is organized into four key sectors: International Business, Contract Research & Manufacturing Services (CRAMS), Companion Animal (CA) Healthcare, and Farm Animal (FA) Healthcare, as well as a specialized division, SAVA Herbals. Its International Business division extends SAVA's reach globally, distributing both human and veterinary pharmaceuticals across North America, Central America, Asia, Africa, and the CIS countries. SAVA is expanding its manufacturing capabilities through an upcoming green field project in Indore that is set to begin commercial operations in 2026.

Renowned for its expertise in Nasal Drug Delivery Platforms, SAVA's CRAMS division has established itself as a reliable partner, catering to a diverse clientele of Indian and international companies. This commitment to quality and innovation positions SAVA Healthcare as a prominent player in the pharmaceutical industry.

SAVAVET CA is one of the largest and most trusted healthcare companies that is committed to lifetime health needs of pets. The division offers the most extensive & exhaustive portfolio of pharmaceuticals and well-being products to enrich lives of companions. SAVAVET FA offers therapeutic and nutritional solutions that are designed to meet the evolving needs of healthcare professionals and farmers in order to keep farm animals healthy and more productive.

For more information visit www.savaglobal.com, www.savavet.com







Introduction

For more than a century, Mars, Incorporated has been driven by the belief that the world we want tomorrow starts with how we do business today. This idea is at the center of who we have always been as a global, family-owned business. Today, Mars is transforming, innovating, and evolving in ways that affirm our commitment to making a positive impact on the world around us. Across our diverse and expanding portfolio of confectionery, food, and petcare products and services, we employ 133,000 dedicated Associates who are all moving in the same direction: forward. With \$40 billion in annual sales, we produce some of the world's best-loved brands including DOVE®, EXTRA®, M&M's®, MILKY WAY®, SNICKERS®, TWIX®, ORBIT®, PEDIGREE®, ROYAL CANIN®, SKITTLES®, BEN'S ORIGINAL™, WHISKAS®, COCOAVIA®, and 5™; and take care of half of the world's pets through our pet health services AniCura, Banfield Pet Hospitals™, BluePearl®, Linnaeus, Pet Partners™, and VCA™. We know we can only be truly successful if our partners and the communities in which we operate prosper as well. The Mars Five Principles – Quality, Responsibility, Mutuality, Efficiency and Freedom – inspire our Associates to take action every day to help create a world tomorrow in which the planet, its people and pets can thrive.

Mars Petcare India

Mars Petcare entered the Indian market in 2002 with its flagship brand PEDIGREE®. The other brands in our portfolio in India are CHAPPI® and IAMS® dog food, WHISKAS®, TASTY MIX and SHEBA® cat foods, DENTASTIX®, BISCROK®, RODEO, TASTY MINIS and JUMBONE®, TEMPTATIONS treats and CATSAN cat litter. Within Mars Petcare, all our pet foods – whether they are specialist or supermarket brands – are built over extensive and evolving research into pet nutrition. Our scientific insights into protein, amino acid, fat content, vitamin and mineral requirements and macronutrient profiles all ensure that we formulate high-quality foods, and we understand different pets' needs, providing appropriate nutrition for different life stages and lifestyles. Mars Petcare is committed to making the world a better place for pets.







Indian Herbs Specialities Pvt. Ltd., established in 1951, is the pioneer and global leader in herbal animal healthcare, with a strong presence across 7 continents and 50+ countries.

Guided by the vision "Nature's Way to Animal Health," Indian Herbs has successfully integrated the wisdom of Ayurveda with modern science to deliver technology-driven, quality-assured, cost-effective, and sustainable phytogenic solutions. The product portfolio comprises 230+ formulations for cattle, poultry, swine, equine, aqua, and companion animals.

INDIAN HERBS has consistently invested in research, innovation, and quality excellence. The company emphasizes herbal standardization, phyto-analytical profiling, and rigorous quality control, while product safety and efficacy are validated through scientific trials conducted in collaboration with premier global research institutes and veterinary universities.

Over the last seven decades, **INDIAN HERBS'** innovations have been featured in 1,250+ scientific publications and 250 postgraduate theses published in reputed national and international journals.

Recognized through numerous national and international awards, the most valued acknowledgment for **Indian Herbs** remains the trust and satisfaction of its customers worldwide. The company's success is rooted in a steadfast commitment to "Value through Innovation" and science-based herbal solutions for sustainable animal health.







HIPRA is a biotechnological pharmaceutical company focused on prevention for animal and human health, with a broad range of highly innovative vaccines. With its claim "Building Immunity for a Healthier World", HIPRA affirms its commitment to contributing with solutions that improve world health. HIPRA has a solid international presence in more than 42 countries, with its own subsidiaries, 11 diagnostic centres and 6 production centres strategically located in Europe (Spain) and America (Brazil). Moreover, its extensive international distribution network keeps open marketing channels with nearly 100 other countries, thereby covering the 5 continents. Research and Development constitute the core of its knowledge. HIPRA dedicates 10% of its annual turnover to R&D activities that concentrate on the creation and application of the latest scientific advances to the development of the highest quality innovative vaccines. To give added value to its vaccination experience, the company also develops medical devices and traceability services. HIPRA performs and monitors all the production stages of its services and biological prod ucts in its facilities, which are equipped with the latest technological advances. HIPRA is the company that has launched the most biotech vaccines in the last 10 years, with a total of 22 vaccines. We are on of the world leaders in the veterinary industry that develop vaccines for animal health. Our staff's integration, their problem-solving ability, and the fact that they share the same values constitute, without a doubt, our most valuable asset







Alivira Animal Health Limited has emerged as India's largest, and 1st Global integrated animal health company specialising in manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF)

Ranked among the top 20 animal health companies in the world, Alivira Animal Health along with its subsidiaries has operations in 90+ countries across the world with 7 manufacturing facilities, serving animal health industry worldwide.

Our commitment lies in advancing veterinary care, offering solutions that promote animal well-being and support the global livestock industry. Through a strong emphasis on quality and sustainability, we deliver products that address the needs of veterinarians and farmers, enhancing animal health worldwide











Vet Formulation Business

Our Formulation for Ruminants include Antimicrobials, NSAIDs, Anti-parasitic, Nutritional Supplement & Supportives. We aim to continuously improve our products by understanding customer needs, expectations and strive hard to bring innovative solutions & services for them

Our Formulation for Poultry Farms include Nutritional Supplements, Antimicrobials, Growth Promoters, Enzymes, Emulsifiers, , Anti-parasitic & Liver Tonic. We partner with farmers and feed mill owners, to enable feed cost optimization, better health and productivity through our R&D-driven product portfolio and technical services

Vet API Business

As a global leader in active pharmaceutical ingredient (API) manufacturing, we are a trusted partner for pharmaceutical companies across more than 90 countries. With strong R&D expertise in synthetic chemistry, analytical chemistry, and process engineering, we have built a robust portfolio of high-quality APIs, including niche segments such as anthelmintics, anti-infectives, and other veterinary APIs. Our advanced research capabilities enable us to meet the evolving needs of the animal health sector, while our commitment to quality ensures excellence in every stage of production. We continue to drive innovation in key therapeutic areas, including livestock, poultry, and companion animal health.

Corporate Social Responsibility

Supporting community aspirations, we believe in fostering inclusive growth and sustainable development. By identifying key areas for focused intervention, we undertake initiatives that drive meaningful and lasting transformation. Our social programmes are designed to support the holistic development of the communities in which we operate





dsm-firmenich

In Animal Nutrition & Health, we help the animal farming industry feed our growing population more sustainably. Our farm-to-fork solutions support farmers in reducing their environmental impact, improving animal performance and welfare, and securing sustainable livelihoods. All while putting healthy, affordable, high-quality animal protein on the table.

We are a diverse team of 7,800 people with a passion for Animal Nutrition & Health and the impact we can make on the food chain, unrivaled expertise, and a unique customer-focused business model. With the most complete portfolio and a unique network of world-class manufacturing and premix sites, we are the only ones to offer Global Products and Local Solutions - with Vitamins, innovative Performance Solutions, and Precision Services.







19 November 2025 | India Habitat Centre, New Delhi

INDIAN IMMUNOLOGICALS LIMITED

Indian Immunologicals Limited (IIL) is a leading biopharma company in India, manufacturing animal health vaccines, human health vaccines, nutraceuticals, and formulations. IIL was established by the National Dairy Development Board (NDDB) in 1982 under the "Operation Flood" programme. IIL operates one of the largest vaccine manufacturing plants in Asia. IIL's commitment for highest standards of quality healthcare



products comes naturally due to its inherent strength in Research, Manufacturing, Quality Management Systems and Customer Service. **IIL is the single largest contributor to India achieving self-sufficiency in the field of vaccines.**

RESEARCH AND DEVELOPMENT



III. has always been in the forefront of research, and more than 60 scientists are engaged to develop several novel vaccines meant for Indian conditions. Several unique vaccines developed for the first time in the world, such as Theileriosis vaccine for cattle, combination vaccines with Foot and Mouth Disease (FMD), Porcine Cysticercosis vaccine. For the first time in India, III. introduced Brucellosis vaccine, Blue Tongue vaccine, gE deleted IBR marker vaccine, 7 in 1 canine vaccines etc which are well accepted in the Indian market. IIL's research team are working on several new animal health vaccines viz, multi-component Clostridia vaccine, Lumpy skin Disease, Mastitis vaccine, Fish Vaccines etc. In human health segment, IIL is working on Chikungunya vaccine, Typhoid vaccine, Zika, Rota Virus, Dengue, and monoclonal antibodies (mabs) etc. MR and Td vaccines have been licensed.

MANUFACTURING CAPABILITIES

IIL is the largest animal vaccine manufacturer in Asia. IIL's two vaccine manufacturing facilities located in Hyderabad. The Gachibowli-Hyderabad facility is engaged in the production of animal and human health vaccines, while the Karakapatla-Hyderabad facility produces animal health formulations and will also produce human vaccines shortly. IIL's Ooty facility exclusively produces human anti-rabies vaccine, "Abhayrab". Apart from this, IIL also operates Pristine Biologicals in New Zealand which processes bovine serum for use in vaccine making, complimenting India's self-sufficiency in the field of vaccines. Another new animal vaccine facility is coming up in Karakapatla, Hyderabad. IIL has been able to develop Covid Drug Substance in record time to augment national demand. This was possible due to sheer technical competence of IIL to develop and deliver Covid drug substance within four months.



LEADERSHIP POSITION



IIL enjoys the leadership position in its animal health vaccines segment. IIL's human anti-rabies vaccine (Abhayrab) is the largest selling brand in India and established its leadership position in several countries in Asia. Abhayrab is the first tissue culture rabies vaccine indigenously developed in India and it's only second only in the world. IIL exports its products to more than 50 countries. IIL's flagship brands,

Raksha-Ovac (FMD vaccine) is one of the largest selling brands in Animal Health market. This is besides several other leading products such as Raksha-Class (CSF vaccine), Raksha-Goat Pox, Rakshavac-T

(Theileriosis), Raksha-SP (Sheep Pox) and several other vaccines for small and large ruminants. Abhayrab (Human anti-rabies vaccine) is a brand leader with sales close to Rs. 500 Cr in 2024-25. IIL is also one of the largest suppliers of animal and human vaccines to Animal Husbandry departments of various state governments and to the Universal Immunisation programme (UIP) of Ministry of Health, Government of India.



BUSINESS CNANNELS

IIL markets its animal health products in dairy milk shed areas, promotes its products to the Veterinarians, paravets etc with various communication tools such as rural campaigns, seminars, digital campaigns etc. IIL also promotes its animal health products to various institutions such as state and central government agencies and various governments in several countries in the international market. IIL's human health products are promoted to various medical practitioners and hospitals through direct and digital campaigns.

NEW INITIATIVES

IIL is expanding its capacities and establishing new viral vaccine production facility in Karakapatla, Hyderabad. This besides its new lyophilized unit which will give higher output for vaccines such as CSF, Brucellosis and several canine

vaccines. A new Greenfield facility for manufacture of FMD vaccine is underway in Karakapatla, Hyderabad, besides another Bovine Serum facility in Australia.

FARMER FIRST

IIL shares NDDB's philosophy in reaching out to the farmers and consumers. Several initiatives or farmers' outreach programmes such as Farmers Contact Programme (FCP), Video-on-Wheels (VOW) programme, Cattle Fairs, Knowledge Upgradation Programme, Mass Vaccination Camps (MVC), Ration Balancing Programme (RBP), Shepherd Contact Programme have immensely benefited the livestock growers.

CORPORATE SOCIAL RESPONSIBILTY



As a part of its Corporate Social Responsibility (CSR), IIL has adopted several schools and provided



infrastructure and nutritional supplements through NDDB's NFN programme. IIL's "Gou-Raksha" project serves as boon to several destitute animals in various Goshalas and Pinjrapole societies. This project is aimed at providing free vaccination and deworming coverage to all these destitute animals. Another important initiative- "Go Green", a biogas plant for conversion of dung into fertilizer is provided as assistance to villages for self-sustenance (part of NDDB initiative). Other important initiatives include – "Utkarsh- Rabies control in Maharashtra"; "Rabies Free Thiruvananthapuram"; "Rural electrification in Muzaffarnagar": Oxygen Plant – for Covid patients in Telangana Institute of Medical Sciences"; "CCTV Cameras- in Siddipet" etc.

NEW PRODUCTS

Since 2016, IIL introduced several animal health vaccines such as ET+TT (Enterotoxaemia and Tetanus) for sheep and goats, Tinea Solium (Vaccine against Porcine Cysticircosis), Raksha-CSF (Classical Swine Fever) vaccine, Raksha Goat Pox (Goat Pox) vaccine, Raksha-IBR (IBR) vaccine etc. In human health, IIL got license to manufacture Pentavalent Vaccine (5 in 1) for children to be used under Universal Immunization Programme of Government of India; first indigenously developed Hepatitis A vaccine in India. MR and Td vaccine being licensed recently.

REVENUES

IIL registered a turnover of Rs.1453 Cr in 2024-25 and has been growing at 10% CAGR

CONTACT US

 $1800\,425\,5363\,/\,1800\,425\,4068$

WEBSITE

www.indimmune.com

KEY PRODUCTS

Segment	Vaccines/Biologicals	Formulations	Nutraceuticals	Top Brands
Animal	Bovine, Canine, Sheep,	Anthelmintics,	Calcium	Raksha-Ovac (FMD Vac)
Health	Goat and Porcine	Analgesics, Antibiotics,	Supplements	Raksharab (Anti-Rabies)
	Vaccines (Viral,	Disinfectants,	Mineral Mixtures	Raksha-Class (CSF); Raksha-
	Bacterial, Protozoal)	Anaesthetics etc	Probiotics, Bypass	Blu (Blue Tongue); Raksha-
			Fats, Vitamins and	Goat Pox (Goat Pox); Nimovet;
			premixes	Calsagar, Goudhara, Gouvit
Human	Anti-Rabies;	Calcium and VitD3;		Abhayrab (Anti-Rabies)
Health	Pentavalent, Hep-B;	Antioxidants; Probiotics		Vaxtar (Pentavalent)
	Hep-A, DPT; TT, Td, MR			Inceptova (Hormones)
	vaccine.			VivaGut (Probiotic)
				Havisure (Hepatitis A)
	Hormones			Abhay-TOX (TT Vaccine)